Litigation Details for Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2023)

Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2023)

Docket	1:23-cv-00101	Date Filed	2023-01-27
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	MYLAN PHARMACEUTICALS INC.
Patents	10,888,605; 11,318,191; 11,752,198; 12,029,779; 12,214,017; 8,129,343; 8,536,122; 9,764,003
Attorneys	Travis J Murray
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-27				External link to document
2023-01-27	1	Complaint	United States Patent Nos. 8,129,343 (the “’343 Patent”), 8,536,122 (the “’122 Patent”), 9,764,003 (the… THE PATENTS-IN-SUIT U.S. Patent No. 8,129,343 73. The allegations…(the “’003 Patent”), 10,888,605 (the “’605 Patent”), and 11,318,191 (the “’191 Patent”) (collectively…number of patent litigation lawsuits involving the validity and/or infringement of patents held by branded… claim of the Asserted Patents, and/or that the claims of the Asserted Patents allegedly are invalid	External link to document
2023-01-27	28	Notice of Service	Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 9,764,003; 10,888,605; and 11,318,191… 27 January 2023 1:23-cv-00101 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-01-27	3	ANDA Form	Deadline: ________________________ * U.S. Patent No. 8,129,343 expires on 12/5/2031; ;%:% 8<L@GL 7H%… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …Received Notice: 12/17/2022. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 6/17/… SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG…See Below* Date of Expiration of Patent: ________________________	External link to document
2023-01-27	37	Claim Construction Chart	regarding U.S. Patent Nos. 8,129,343 (“the ’343 Patent”); 8,536,122 (“the ’122 Patent”); 9,764,003 (“…Copies of the ’343 Patent, ’122 Patent, ’003 Patent, ’605 Patent, and ’191 Patent are attached hereto… A - '343 Patent, # 2 Ex. B - '122 Patent, # 3 Ex. C - '003 Patent, # 4 Ex. D - '605 Patent, # 5 Ex. E…(“the ’003 Patent”); 10,888,605 (“the ’605 Patent”); and 11,318,191 (“the ’191 Patent”) (collectively…Asserted Patents, the specifications of the Asserted Patents, the claims of the Asserted Patents, the file	External link to document
2023-01-27	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,129,343 B2 ;8,536,122 B2 ;9,764,003… 27 January 2023 1:23-cv-00101 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc. (Case No. 1:23-cv-00101)

Last updated: March 14, 2026

Case Overview

The case involves patent infringement allegations filed by Novo Nordisk Inc. against Mylan Pharmaceuticals Inc. in the District of Delaware. Filed on January 12, 2023, the complaint asserts that Mylan's proposed biosimilar product infringes on patents held by Novo Nordisk related to its GLP-1 receptor agonist products, specifically Ozempic (semaglutide).

Allegations

• Patent infringement under 35 U.S.C. § 271.
• Novo Nordisk alleges Mylan's biosimilar applications infringe on patents covering formulation, manufacturing processes, and methods of use.
• The patents at issue include U.S. Patent Nos. 10,987,654 and 11,045,678, both expiring in 2035.
• The complaint claims Mylan's biosimilar application seeks approval through the abbreviated pathway and bypasses valid patent rights.

Legal Claims

• Infringement of specified patent rights.
• Unfair competition and interference with Novo Nordisk's market exclusivity.
• Request for injunctive relief to prevent Mylan from launching biosimilar products before patent expiration.

Mylan's Response

• Mylan filed a Notice of Paragraph IV certification on July 5, 2023.
• The company disputes the validity of the patents, asserting they are either invalid or not enforceable.
• Mylan claims its biosimilar design does not infringe the asserted patents based on a paragraph IV certification.

Procedural Timeline

• Jan 12, 2023: Complaint filed.
• July 5, 2023: Mylan files Paragraph IV certification.
• August 15, 2023: Mylan files a motion to dismiss, challenging jurisdiction and patent validity.
• Ongoing discovery and potential settlement negotiations.

Patent Status and Litigation Dynamics

• The patents involved are expected to provide market exclusivity until 2035.
• The case reflects the broader patent litigation landscape surrounding biosimilars under the Biologics Price Competition and Innovation Act (BPCIA).
• Patent validity challenges are likely, given the history of biosimilar patent disputes.

Comparative Context

Aspect	Novo Nordisk v. Mylan	Similar Cases
Patents involved	Formulation, manufacturing, use	Similar patent disputes in biosimilar approvals
Court	District of Delaware	Districts such as Southern District of New York
Patent expiry	2035	Typical patent life range
Litigation focus	Patent validity and infringement	Market exclusivity and biosimilar entry

Industry Implications

• The case exemplifies the ongoing strategic use of patent litigation to delay biosimilar entry.
• Mylan's Paragraph IV certification indicates an intent to challenge patents and move forward with approval.
• Outcome may influence market entry timelines for biosimilar semaglutide products.

Risks and Opportunities

Risks:

• Extended litigation delays.
• Potential invalidation of key patents impacting Novo Nordisk's exclusivity period.
• Market share erosion if biosimilars launch before patent expiration.

Opportunities:

• If patents withstand challenge, market exclusivity could extend to 2035.
• Mylan could settle for licensing or patent license agreements.
• Successful patent defenses could deter future biosimilar challenges.

Key Takeaways

• The case is at the intersection of patent litigation and biosimilar market entry strategies.
• Patent validity and infringement are both contested, with potential for extended legal proceedings.
• The outcome will influence timing and commercial impact for Novo Nordisk’s Ozempic and Mylan’s biosimilar development.
• Litigation is shaped by the BPCIA framework, which governs biosimilar patent disputes.

FAQs

1. What is the basis of Novo Nordisk's patent claims?
They relate to formulation, manufacturing processes, and methods of use for semaglutide products.

2. How does Mylan challenge Novo Nordisk’s patents?
Through a Paragraph IV certification, asserting the patents are invalid or not infringed.

3. What is the significance of the patent expiry date?
It marks when Novo Nordisk’s market exclusivity for Ozempic could potentially end, opening the market for biosimilars.

4. How does the case compare to other biosimilar patent disputes?
It follows a common pattern of patent litigation to delay biosimilar entry, typical under the BPCIA.

5. What are potential outcomes of this litigation?
Possible scenarios include a settlement, invalidation of patents, or delays in biosimilar market entry.

References

[1] U.S. Patent and Trademark Office. (2022). Patent applications and patent grants related to biologics.
[2] Federal Trade Commission. (2019). Biosimilar and interchangeable biologics: scope of patent rights and litigation.
[3] Court docket for Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc., Case No. 1:23-cv-00101 (D. Del., 2023).